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Introduction
T cells and macrophages are considered to play an impor-
tant role in the initiation and perpetuation of inflammatory
responses in rheumatoid arthritis (RA) [1–3]. Stimulation
of macrophages can be mediated by activated memory
CD4+ T cells that are abundantly present in the inflamed
joints of RA patients [2,4,5]. In this respect, many studies
have focused on the balance of Th1 and Th2 cells. The
Th1 subset has been defined by the specific production of
IFN-γ and IL-2, and by the stimulation of cell-mediated
immunity, whereas the Th2 subset specifically produces
IL-4 and stimulates humoral immunity [6,7]. Based on
analysis of IFN-γ and IL-4 production, a dominance of Th1
cell activity over Th2 cell activity has been shown in the
inflamed joints of RA patients [8,9]. This imbalance of
Th1/Th2 cells was shown to correlate with disease activity
scores [10]. Although IL-4 production by T cells from the
peripheral blood of RA patients is increased compared
with that of healthy controls, this Th2 activity seems to be
insufficient to control Th1-associated inflammation in RA
[11–13].
IL-4 and other suppressive cytokines that can be pro-
duced by Th2 cells (e.g. IL-10 and IL-13) suppress activity
of several cell types that contribute to inflammation in the
RA joints [14–16]. In vitro and in vivo induction of Th2 cell
DMEM = Dulbecco’s modified Eagle’s medium; ELISA = enzyme-linked immunosorbent assay; FACS = fluorescence-activated cell sorting; IFN =
interferon; IL = interleukin; RA = rheumatoid arthritis; TCR = T-cell receptor; Th = T helper.
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Abstract
An impaired differentiation of naive CD4+ T cells towards Th2
cells may contribute to the chronic tissue-destructive T-cell
activity in rheumatoid arthritis (RA). The differentiation of
naive CD4+ T cells into memory Th2 cells by IL-7 in
comparison with that by IL-4 was studied in RA patients and
in healthy controls. Naive CD4+ T cells from peripheral blood
were differentiated by CD3/CD28 costimulation in the
absence of or in the presence of IL-7 and/or IL-4. The
production of IFN-γ and IL-4 was measured by ELISA and by
single-cell FACS analysis to indicate Th1 and Th2 cell
activity. CD3/CD28 costimulation and IL-7 were early
inducers of IL-4 production, but primarily stimulated IFN-γ
production. In contrast, in short-term cultures exogenously
added IL-4 did not prime for IL-4 production but
suppressed IL-7-induced IFN-γ production. Upon long-term
stimulation of naive CD4+ T cells, IFN-γ production was
differentially regulated by IL-7 and IL-4, but IL-4 production
was increased by both IL-7 and IL-4. IL-7 and IL-4
additively induced polarization towards a Th2 phenotype.
This susceptibility of naive CD4+ T cells to become Th2
cells upon culture with IL-7 and IL-4 was increased in RA
patients compared with that in healthy controls. These
findings demonstrate that, in RA patients, differentiation of
naive CD4+ T cells towards a Th2 phenotype by CD3/CD28
costimulation, IL-7 and IL-4 is not impaired. The perpetuation
of arthritogenic T-cell activity in RA therefore seems not to be
the result of intrinsic defects of naive CD4+ T cells to develop
towards suppressive memory Th2 cells.
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activity has been associated with anti-inflammatory
responses and disease suppression in RA [4,17]. Induc-
tion of Th2 cell activity as well as administration of Th2
cytokines can offer protection against experimental colla-
gen-induced arthritis [18,19]. Prevention of joint destruc-
tion is shown to be the final result of such elevated Th2
activity [17,20,21]. Together these data suggest that RA
patients may benefit from therapies aimed at the regula-
tion of the Th cell balance towards Th2 cell activity. It also
implies that intrinsic defects in the responsiveness of
T cells to factors that can support the generation of Th2
cell activity, in peripheral lymphoid tissues and at the
inflammatory sites, could cause or contribute towards RA.
The activation of naive CD4+ T cells towards IL-4-produc-
ing Th2 cells has been shown to require signaling through
the TCR/CD3 complex together with costimulation. Since
memory cells are less dependent on such costimulation to
produce IL-4, in particular the development of naive CD4+
T cells towards Th2 cells may be disturbed in RA patients.
Circulating naive CD4+ T cells can enter areas of primary
T-cell stimulation and can interact with antigen-presenting
cells. Here naive cells can differentiate into memory effec-
tor Th cells. Factors that drive the initial expression of IL-4
(as the major Th2-defining cytokine) in human naive CD4+
T cells include costimulation via CD28 in concerted action
with TCR engagement [22]. It has been shown in humans
[22,23] and in mice [24,25] that, in an autocrine way, the
initial endogenous IL-4 production, or IL-4 from other
sources, can stimulate the development of IL-4-producing
CD4+ T cells. To achieve this, naive CD3-activated T cells
need to be stimulated in the presence of CD28 costimula-
tion [22,23,26,27]. This is in contrast to (human) memory
CD4+ T cells, which can produce IL-4 upon CD3 stimula-
tion alone, but production is more pronounced when cul-
tured in the presence of IL-4 [22]. IL-7, in contrast to IL-4,
has recently been shown to prime human naive neonatal
CD4+ T cells for IL-4 production in the absence of CD28
costimulation [27]. Thus, in humans, IL-7 produced by
stromal cells in the peripheral lymphoid organs that play an
important role in lymphocyte development, including the
lymph nodes, the spleen and the mucosal lymphoid
tissues, may be more effective (than IL-4) in driving naive
CD4+ T cells to a Th2 phenotype [28].
The shortage of suppressive Th2 activity in RA patients
[8–10] is assumed to be involved in the chronic inflamma-
tory activity in these patients. This shortage may be the
result of a defect in the capacity of naive CD4+ T cells to
respond adequately to stimuli such as TCR(CD3)/CD28
costimulation, IL-7 and IL-4, and by that to become Th2
cells. Recent studies have shown that IL-7 is produced by
activated synovial fibroblasts from RA patients [29], and
that circulating levels of IL-7 were shown to correlate with
markers of disease [30]. The present study evaluated
whether circulating naive CD4+ T cells displayed an
impaired response to IL-7 (and IL-4), and demonstrates
that such a defect is not present in RA patients. In con-
trast, differentiation by IL-7 and IL-4 towards Th2 cell
activity was increased in RA patients.
Methods
Patients
Mononuclear cells were isolated from the peripheral blood
of a total of nine randomly selected patients with RA and
of nine healthy age-matched controls. RA was defined by
the 1987 revised American College of Rheumatology cri-
teria [31]. Patients (seven females and two males) ranged
in age from 33 to 73 years with a mean age of
53±13 years. Seven patients were rheumatoid factor-
positive and two patients were rheumatoid factor-negative.
Seven patients received nonsteroidal anti-inflammatory
drugs, five patients took slow-acting antirheumatic drugs,
and two patients were on low-dose prednisone. Healthy
controls ranged in age from 37 to 72 years with a mean
age of 50±14 years, not statistically significant different
from the RA group.
Cell cultures and reagents
Peripheral blood was diluted 1:1 with DMEM (Gibco 074-
01600, 24mM NaHCO3; Gibco, New York, USA) contain-
ing glutamine (2mM), penicillin (100U/ml) and streptomycin
sulfate (100µg/ml; DMEM+). Mononuclear cells were iso-
lated by density centrifugation using Ficoll-Paque (Pharma-
cia, Uppsala, Sweden). The viability of the cells, checked by
trypan blue exclusion, was always more than 95%.
CD4+ T cells were isolated from the peripheral blood
mononuclear cells by means of microbead-activated cell
sorting according to the manufacturer’s instructions
(Mylteni Biotec, Bergisch Gladbach, Germany). Briefly,
depletion of CD4-negative T cells was achieved by incu-
bation of peripheral blood mononuclear cells with a cock-
tail of monoclonal antibodies directed against non-T cells
and against CD4-negative T cells, followed by binding of a
secondary microbead-coupled antibody to bind to the
primary antibodies. Microbead-labeled cells were removed
by binding to a magnet. CD45RA+ (naive) T cells were
obtained by depleting the CD4+ population of CD45RO+
(memory) T cells, using microbead-coupled CD45RO anti-
bodies. The purity of the CD4+CD45RA+ T-cell population
was checked by FACS analysis, and exceeded 95%.
These naive CD4+CD45RA+ T cells were cultured
(5×10 5cells/ml) in DMEM+ supplemented with 10%
pooled human male AB serum (Red Cross Blood Transfu-
sion Centre, Utrecht, The Netherlands) and soluble
CD3/CD28 monoclonal antibodies (1µg/ml) (CLB-T3/4.E
and CLB-CD28, respectively; CLB Reagentia, Amsterdam,
The Netherlands [32]) for 10 days. Cells were washed
three times on day 5 and seeded at a concentration of
1×10 6 cells/ml for the subsequent 5-day culture. CellsR271
were stimulated with or without IL-7 (Genzyme, Cam-
bridge, MA, USA), with or without IL-4 (a kind gift from Dr
S Narula, Schering-Plough Research Institute, Kenilworth,
NJ, USA), or with or without IL-7 and IL-4 (both 10ng/ml).
Cytokine analysis
IFN-γ and IL-4 production were analyzed by ELISA upon
costimulation with CD3/CD28 and cytokines after 5 days
of culture. After both 5 and 10 days of culture, cells were
extensively washed (three times), seeded at a concentra-
tion of 106 cells/ml and restimulated with ionomycin
(1µg/ml; Sigma, St Louis, MO, USA) and phorbol myris-
tate acetate (50ng/ml; ICN Pharmaceuticals, Costa Mesa,
CA, USA) for 24 hours. The media were harvested and
freed of cellular material by centrifugation (5 min, 900×g),
frozen in liquid nitrogen and stored below –20°C. IFN-γ
and IL-4 in the culture supernatant was determined by
ELISA according to the manufacturer’s instructions (Med-
genix, Flerus, Belgium).
FACS analysis was used for IFN-γ and IL-4 analysis at the
single cell level. After cells had been cultured for 10 days
they were extensively washed, were seeded at a concen-
tration of 106 cells/ml and were stimulated with iono-
mycin/phorbol myristate acetate for 6 hours. To enhance
intracellular fluorescence, protein secretion was inhibited
by the addition of 10µg/ml Brefeldin A (ICN Pharmaceuti-
cals) during the final 2 hours of culture. The cells were
fixed and permeabilized with a fixation and permeabiliza-
tion kit, according to the manufacturer’s instructions
(Caltag Laboratories, Burlingame, CA, USA). Fluo-
rochrome-labeled anti-IFN-γ, anti-IL-4 and isotype control
antibodies (Caltag Laboratories) were added during the
permeabilization step (1µg/ml) to stain the intracellular
cytokines. Fluorescence was analyzed with a FACScan
(Becton Dickinson, Mountain View, CA, USA). The quad-
rant markers for the bivariate dot plots were set based on
the autofluorescence control, and they were verified with
isotype control antibodies.
Statistical analysis
Statistical evaluation of differences in cytokine production
was performed by the Wilcoxon and Mann–Whitney U
tests when appropriate. Data were considered statistically
significant at P<0.05.
Results
Short-term costimulation with CD3/CD28 and IL-7 but
not with IL-4 induces IL-4 production in naive CD4+ T cells
Although CD45RA+ CD4+ T cells in RA patients can be
isolated from the inflammatory sites (synovial fluid and
tissue), many inflammatory stimuli in these compartments
can modulate their activity. CD45RA+ CD4+ cells from the
joint were therefore not used as truly naive CD4+ cells, but
instead circulating CD45RA+ CD4+ T cells from the
peripheral blood were used as primary naive cells.
CD3/CD28 costimulation of naive CD4+ T cells from RA
patients for 5 days induced large amounts of IFN-γ and
only limited amounts of IL-4 (10.0±4.7ng/ml and
267±110pg/ml, respectively). The IFN-γ production of
this ex vivo population was significantly lower than that of
healthy controls (32.2±9.7ng/ml, P<0.05), whereas IL-4
production (288±82pg/ml) was not significantly different.
IL-7 enhanced both IFN-γ and IL-4 production of costimu-
lated naive CD4+ T cells from RA patients, whereas IL-4
significantly inhibited IFN-γ production, both in the
absence of and in the presence of IL-7 (Fig.1). These
effects were not different in healthy controls (data not
shown).
To measure the effects of exogenously added IL-4 (and
IL-7), cells from RA patients were washed extensively and
restimulated with ionomycin/phorbol myristate acetate
(Fig.2a). This restimulation resulted in increased produc-
tion of IFN-γ and IL-4 (control cultures of Figs1 and 2a).
IL-7 pretreatment had significantly sensitized the naive
CD4+ T cells for increased IL-4 production compared with
the control culture, whereas IFN-γ was not significantly
increased by IL-7. In contrast to IL-7, addition of exoge-
nous IL-4 during the primary stimulation had not primed
T cells for increased IL-4 production, but had strongly sup-
pressed IFN-γ production. IL-7 added together with IL-4
resulted in a further increase of IL-4 production and a sig-
nificantly decreased IFN-γ production compared with IL-7
and IL-4 alone.
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Figure 1
IFN-γ and IL-4 production of CD3/CD28 costimulated naive CD4+
T cells from rheumatoid arthritis patients (n=9) stimulated for 5 days in
the presence of IL-7. Because of exogenously added IL-4, only the
production of IFN-γ is shown for cells cultured in the presence of IL-4
or of IL-7 and IL-4. *P<0.05, statistically significant differences versus
control cultures in the absence of added cytokines (con). A significant
difference between IL-7 and IL-7/IL-4 is also indicated (**P<0.01).
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Long-term culture with IL-7 and IL-4 induces IL-4-
producing memory cells
The effect of IL-7 and/or IL-4 on the production of IFN-γ
(Th1) and IL-4 (Th2) production during long-term culture
of CD45RA+ CD4+ T cells is depicted in Fig.2b. After this
culture of naive (CD45RA+) CD4+ T cells from RA
patients (Figs 2b and 3) and from healthy controls (Fig.3)
for 10 days, nearly all cells were differentiated into
CD45RO+ memory T cells (Fig.4). IL-7 alone did not
change IFN-γ production under these conditions, but it still
enhanced IL-4 production. Long-term exposure to IL-4
suppressed IFN-γ production and, in contrast to short-
term culture, increased IL-4 production. The combination
of IL-7 and IL-4 reduced IFN-γ levels and additively
enhanced IL-4 production (Fig.2b). Inhibition of IFN-γ pro-
duction by IL-7 and IL-4 was significantly different from
IL-7 alone, but not statistically different from IL-4 alone.
With respect to the increase of IL-4, the combination was
significantly additive to the effect of either IL-7 or IL-4
alone.
Differentiation of naive CD4+ T cells by IL-7 and IL-4 is
not impaired in RA patients
The differentiation of naive CD4+ T cells towards the Th2
memory phenotype was not impaired in RA patients when
compared with healthy controls (Fig.3). Regulation of
IFN-γ production of CD4+ T cells in RA patients by IL-7
alone, by IL-4 alone or by IL-7 and IL-4 was not signifi-
cantly different from healthy controls (Fig.3, left panel).
The percentage increase in IL-4 production after differenti-
Figure 2
IFN-γ and IL-4 production of CD3/CD28 costimulated naive CD4+ T cells from rheumatoid arthritis patients (n=9) differentiated during (a) 5-day
cultures or (b) 10-day cultures in the presence of IL-7, of IL-4, or of IL-7 and IL-4. Cytokine production of differentiated cells was analyzed upon
ionomycin/phorbol myristate acetate restimulation for 24 hours. *P<0.05 **P<0.01, statistically significant differences versus control cultures in
the absence of added cytokines (con). Significant differences between the cytokine treatments are indicated separately.
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Figure 3
The production of IFN-γ and IL-4 by CD3/CD28 costimulated naive CD4+ T cells from healthy controls (n=9, white bars) and rheumatoid arthritis
(RA) patients (n=9, black bars) differentiated during 10 days of culture in the presence of IL-7, of IL-4 or of IL-7 and IL-4. Cytokine production of
differentiated cells was analyzed upon ionomycin/phorbol myristate acetate restimulation for 24 hours. Values are expressed as percentages of
cytokine levels produced in the absence of exogenously added cytokines (control values set at 100% for RA patients and controls, respectively,
were 47.1±12ng/ml versus 37.1±5.7ng/ml for IFN-γ, and 0.89±0.21ng/ml versus 0.95±0.15ng/ml for IL-4; not significantly different).
#P<0.05, statistically significant differences between RA patients and healthy controls; *P<0.05, **P<0.01, statistically significant differences
between control and cytokine-treated cultures.
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Figure 4
Differentiation of naive CD4+ T cells (CD45RA+) towards memory CD4+ T cells (CD45RO+) in rheumatoid arthritis (RA) patients and in healthy
controls after CD3/CD28 costimulation for 5 and 10 days. The numbers in each quadrant indicate the percentage of CD45RA+ (upper left),
CD45RO+ (lower right) and CD45RA+ CD45RO+ double positive cells (upper right). PE, phycoerythrin; FITC, fluorescein isothiocyanate.
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Figure 5
Intracellular detection of IFN-γ and IL-4 by FACS analysis. (a) A representative of seven rheumatoid arthritis (RA) patients of which mean values are
shown in (b). Cytokine production of the CD3/CD28 costimulated CD4+ T cells was assessed after 10 days of culture in the absence or presence
of IL-7, of IL-4 or of their combination. Cytokine production of differentiated cells was analyzed upon ionomycin/phorbol myristate acetate
stimulation for 6 hours in the presence of Brefeldin A. Means ± standard errors of the mean of percentages from cells of RA patients that produce
IFN-γ but no IL-4 (Th1) and that produce IL-4 but no IFN-γ (Th2) upon differentiation are shown. *P<0.05, **P<0.01, statistically significant
differences between control (con) culture and cultures with IL-7, with IL-4 or with IL-7 and IL-4. Significant differences between the cytokine
treatments are indicated separately. PE, phycoerythrin; FITC, fluorescein isothiocyanate.
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*ation by IL-7 and IL-4 was higher in RA patients than in
healthy controls. The additive induction of IL-4 by com-
bined differentiation with IL-7 and IL-4 was even signifi-
cantly higher in RA patients (Fig.3, right panel).
Single-cell analysis was performed to verify polarization of
the RA CD4+ T cells after differentiation towards either a
Th1 or a Th2 phenotype (Fig.5a is representative of FACS
analysis, and Fig.5b shows the average percentages of
Th1 and Th2 cells of seven RA patients). Without IL-7 or
IL-4, a large number of the CD4+ T cells produced IFN-γ
but no IL-4 (Th1, average 23.5%), whereas few cells pro-
duced IL-4 but no IFN-γ (Th2, average 5.9%). In control
cultures a Th0 phenotype was found, on average, in
3.6±0.9%, whereas 73.1±2.4% was double negative.
The numbers of Th0 and double negative cells were not
significantly changed by IL-7, by IL-4 or by their combina-
tion (data not shown). The numbers of Th1 and Th2 cells
resembled cytokine secretion profiles (Fig.2b). IL-7 did
not significantly alter the number of Th1 cells, whereas
IL-4 reduced this number. However, both IL-7 and IL-4
increased the number of Th2 cells. Furthermore, IL-7 and
IL-4 additively decreased the number of Th1 cells and
additively increased the number of Th2 cells.
Discussion
The apparent shortage of Th2 cell activity in the RA
patients has been suggested to contribute to the ongoing
inflammation in RA patients [4,5,8–10]. A deficiency of
primary naive CD4+ T cells of RA patients to respond to
IL-4-inducing factors was the hypothesis of the present
study. The differentiation of naive CD4+ T cells towards
IL-4-producing Th2 cells requires stimulation through the
TCR/CD3 complex together with costimulatory signals.
Since memory cells do not require this costimulation, in
particular the development of naive CD4+ T cells towards
Th2 cells was hypothesized to be impaired in RA patients.
In line with earlier studies [22,26], we found that a rela-
tively short activation period (the first 5 days of culture) of
naive CD4+CD45RA+ T cells from RA patients through
the TCR/CD3 complex together with CD28 costimulation
by itself induces IL-4. Furthermore, it was found that
during this period IL-7, but not IL-4, is a soluble factor for
early IL-4 induction in naive CD4+ T cells in (adult) RA
patients, which has also been described for human neo-
natal naive CD4+ T cells [27]. The fact that IL-4 is not an
early differentiation factor for naive CD4+ T cells is in line
with data from adult healthy controls [26]. Upon long-term
culture, however, which is associated with the acquire-
ment of the memory phenotype, exogenously added IL-4
also increases the endogenous IL-4 production and per-
sistently inhibits IFN-γ production. Most important, with
respect to IL-4 induction, there was no lack in responsive-
ness to IL-7, to IL-4 or to their combination in RA patients
compared with in healthy controls. On the contrary, induc-
tion of IL-4 was even more pronounced for RA patients
than for healthy controls.
Although we show that IL-7, and in particular the combina-
tion of IL-7 and IL-4, increased Th2 activity rather than Th1
activity of naive CD4+ T cells, this was only found under
conditions where IFN-γ production was already maximally
stimulated. In the absence of CD3/CD28 costimulation or
less optimal stimulatory conditions (data not shown), we
and other workers have found that IL-7 increases primarily
IFN-γ production of isolated naive CD4+ T cells [27]. In
agreement with this capacity to induce arthritogenic T-cell
activity in RA patients, we have found that IL-7, in the
context of synovial accessory cells, strongly stimulates
T-cell IFN-γ and tumor necrosis factor alpha production
without induction of IL-4 [30]. IL-7 produced by fibroblast-
like synoviocytes in RA joints is therefore suggested to
contribute to the local inflammatory response [29].
However, IL-7 under certain conditions or at sites different
from the joint could promote regulatory T-cell activity.
Increased levels of circulating IL-7 in patients with RA and
juvenile idiopathic (rheumatoid) arthritis [30,33] correlated
with increased parameters of disease. Since increased
peripheral Th2 cell activity has also been observed to cor-
relate with increased disease activity in RA patients
[11–13], it can be speculated that circulating IL-7 or IL-7
produced in peripheral lymphoid organs [28] may con-
tribute to this relatively enhanced peripheral Th2 activity in
RA patients compared to healthy controls. The reduced
capacity of Th2 cells to migrate to the arthritic sites could
subsequently facilitate the presence of these cells in the
peripheral blood and their absence in the joint [34].
The present study suggests that the chronic immune
response in RA is not caused by an intrinsic defect of
naive CD4+ T cells of these patients to produce IL-4 in
response to costimulation and differentiating factors such
as IL-7 (and IL-4). Therapies aimed at the regulation of
disease activity by induction of suppressive Th2 cell activ-
ity in RA therefore do not seem to be hampered by an
intrinsic defect of naive T cells to respond to IL-4-inducing
stimuli.
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